Experimental therapeutics of neurodegenerative disorders: Unmet needs

Science

Volumn 282, Issue 5391, 1998, Pages 1072-1079

  Shoulson, Ira ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; REMACEMIDE; SELEGILINE; UBIDECARENONE;

ALZHEIMER DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HUNTINGTON CHOREA; NERVE DEGENERATION; NEUROMODULATION; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; WILSON DISEASE;

ANIMALIA;

EID: 0032491507     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.282.5391.1072     Document Type: Review

References (42)

1. P. J. Whitehouse et al., Science 215, 1237 (1982); K. L. Davis et al., N. Engl. J. Med. 237, 1253 (1992); S. L. Rogers, R. S. Doody, R. C. Mohs, L. T. Friedhoff, Arch. Int. Med. 158, 1021 (1998).
2. P. J. Whitehouse et al., Science 215, 1237 (1982); K. L. Davis et al., N. Engl. J. Med. 237, 1253 (1992); S. L. Rogers, R. S. Doody, R. C. Mohs, L. T. Friedhoff, Arch. Int. Med. 158, 1021 (1998).
3. P. J. Whitehouse et al., Science 215, 1237 (1982); K. L. Davis et al., N. Engl. J. Med. 237, 1253 (1992); S. L. Rogers, R. S. Doody, R. C. Mohs, L. T. Friedhoff, Arch. Int. Med. 158, 1021 (1998).
4. H. Braak and E. Braak, in Neurodegenerative Diseases, D. B. Calne, Ed. (Saunders, Philadelphia, 1994), pp. 585-613.
5. G. C. Cotzias, M. H. VanWoert, L. M. Schiffer, N. Engl. J. Med. 276, 374 (1967); K. G. Lloyd, L. Davidson, O. Hornykiewicz, J. Pharmacol. Exp. Ther. 195, 453 (1975); D. B. Calne, N. Engl. J. Med. 329, 1021 (1993); R. J. Uitti, J. E. Ahlskog, CNS Drugs 5, 369 (1996)
6. G. C. Cotzias, M. H. VanWoert, L. M. Schiffer, N. Engl. J. Med. 276, 374 (1967); K. G. Lloyd, L. Davidson, O. Hornykiewicz, J. Pharmacol. Exp. Ther. 195, 453 (1975); D. B. Calne, N. Engl. J. Med. 329, 1021 (1993); R. J. Uitti, J. E. Ahlskog, CNS Drugs 5, 369 (1996)
7. G. C. Cotzias, M. H. VanWoert, L. M. Schiffer, N. Engl. J. Med. 276, 374 (1967); K. G. Lloyd, L. Davidson, O. Hornykiewicz, J. Pharmacol. Exp. Ther. 195, 453 (1975); D. B. Calne, N. Engl. J. Med. 329, 1021 (1993); R. J. Uitti, J. E. Ahlskog, CNS Drugs 5, 369 (1996)
8. G. C. Cotzias, M. H. VanWoert, L. M. Schiffer, N. Engl. J. Med. 276, 374 (1967); K. G. Lloyd, L. Davidson, O. Hornykiewicz, J. Pharmacol. Exp. Ther. 195, 453 (1975); D. B. Calne, N. Engl. J. Med. 329, 1021 (1993); R. J. Uitti, J. E. Ahlskog, CNS Drugs 5, 369 (1996)
9. S. E. Andrew, Y. P. Goldberg, M. R. Hayden, Hum. Mol. Genet. 6, 2005 (1997); J. F. Gusella, F. Persichetti, M. E. MacDonald, Mol. Med. 3, 238 (1997).
10. S. E. Andrew, Y. P. Goldberg, M. R. Hayden, Hum. Mol. Genet. 6, 2005 (1997); J. F. Gusella, F. Persichetti, M. E. MacDonald, Mol. Med. 3, 238 (1997).
11. R. L. Albin, A. Reiner, K. D. Anderson, J. B. Penney, A. B. Young, Ann. Neurol. 27, 357 (1990); J. T. Greenamyre and I. Shoulson, in (2), pp. 685-704.
12. R. L. Albin, A. Reiner, K. D. Anderson, J. B. Penney, A. B. Young, Ann. Neurol. 27, 357 (1990); J. T. Greenamyre and I. Shoulson, in (2), pp. 685-704.
13. I. Shoulson and the Parkinson Study Group, Ann. Neurol. 44 (suppl. 1), S160 (1998).
14. C. W. Olanow, P. Jenner, M. Youdim, Eds., Neurodegeneration and Neuroprotection in PD (Academic Press, New York, 1996);
15. P. R. Bär and M. F. Beal, Eds., Neuroprotection in CNS Diseases (Dekker, New York, 1997).
16. L. J. Martin et al., Am. J. Pathol. 145, 1358 (1994); D. L. Price, S. S. Sisodia, S. E. Gandy, Curr. Opin. Neurol. 8, 268 (1995); M. H. Polymeropoulos et al., Science 276, 2045 (1997); M. G. Spillantini et al., Nature 388, 839 (1997); C. A. Ross, Neuron 19, 1147 (1997); M. DiFiglia et al., Science 277, 1990 (1997).
17. L. J. Martin et al., Am. J. Pathol. 145, 1358 (1994); D. L. Price, S. S. Sisodia, S. E. Gandy, Curr. Opin. Neurol. 8, 268 (1995); M. H. Polymeropoulos et al., Science 276, 2045 (1997); M. G. Spillantini et al., Nature 388, 839 (1997); C. A. Ross, Neuron 19, 1147 (1997); M. DiFiglia et al., Science 277, 1990 (1997).
18. L. J. Martin et al., Am. J. Pathol. 145, 1358 (1994); D. L. Price, S. S. Sisodia, S. E. Gandy, Curr. Opin. Neurol. 8, 268 (1995); M. H. Polymeropoulos et al., Science 276, 2045 (1997); M. G. Spillantini et al., Nature 388, 839 (1997); C. A. Ross, Neuron 19, 1147 (1997); M. DiFiglia et al., Science 277, 1990 (1997).
19. L. J. Martin et al., Am. J. Pathol. 145, 1358 (1994); D. L. Price, S. S. Sisodia, S. E. Gandy, Curr. Opin. Neurol. 8, 268 (1995); M. H. Polymeropoulos et al., Science 276, 2045 (1997); M. G. Spillantini et al., Nature 388, 839 (1997); C. A. Ross, Neuron 19, 1147 (1997); M. DiFiglia et al., Science 277, 1990 (1997).
20. L. J. Martin et al., Am. J. Pathol. 145, 1358 (1994); D. L. Price, S. S. Sisodia, S. E. Gandy, Curr. Opin. Neurol. 8, 268 (1995); M. H. Polymeropoulos et al., Science 276, 2045 (1997); M. G. Spillantini et al., Nature 388, 839 (1997); C. A. Ross, Neuron 19, 1147 (1997); M. DiFiglia et al., Science 277, 1990 (1997).
21. L. J. Martin et al., Am. J. Pathol. 145, 1358 (1994); D. L. Price, S. S. Sisodia, S. E. Gandy, Curr. Opin. Neurol. 8, 268 (1995); M. H. Polymeropoulos et al., Science 276, 2045 (1997); M. G. Spillantini et al., Nature 388, 839 (1997); C. A. Ross, Neuron 19, 1147 (1997); M. DiFiglia et al., Science 277, 1990 (1997).
22. J. H. Menkes, in The Molecular and Genetic Basis of Neurological Disease, R. N. Rosenberg, S. B. Pruisner, S. DiMauro, R. L. Barchi, Eds. (Butterworth-Heineman, Newton, MA, 1997), pp. 1273-1290; R. F. Pfeiffer, in Movement Disorders: Neurologic Principles and Practice, R. L. Watts and W. C. Koller, Eds. (McGraw-Hill, New York, 1997), pp. 623-637.
23. J. H. Menkes, in The Molecular and Genetic Basis of Neurological Disease, R. N. Rosenberg, S. B. Pruisner, S. DiMauro, R. L. Barchi, Eds. (Butterworth-Heineman, Newton, MA, 1997), pp. 1273-1290; R. F. Pfeiffer, in Movement Disorders: Neurologic Principles and Practice, R. L. Watts and W. C. Koller, Eds. (McGraw-Hill, New York, 1997), pp. 623-637.
24. Parkinson Study Group, N. Engl. J. Med. 328, 176 (1993); Ann. Neurol. 39, 29 (1996); ibid., p. 37; ibid. 43, 318 (1998).
25. Parkinson Study Group, N. Engl. J. Med. 328, 176 (1993); Ann. Neurol. 39, 29 (1996); ibid., p. 37; ibid. 43, 318 (1998).
26. Parkinson Study Group, N. Engl. J. Med. 328, 176 (1993); Ann. Neurol. 39, 29 (1996); ibid., p. 37; ibid. 43, 318 (1998).
27. Parkinson Study Group, N. Engl. J. Med. 328, 176 (1993); Ann. Neurol. 39, 29 (1996); ibid., p. 37; ibid. 43, 318 (1998).
28. M. Sano et al., N. Engl. J. Med. 336, 1216 (1997).
29. NINDS Clinical Trial Planning Grant, NIH Guide, vol. 26 (no. 29), 29 August 1997 (PA no.: PAR-97-1020).
30. D. W. Paty and D. K. B. Li, Neurology 43, 662 (1993).
31. J. P. Seibyl et al, Ann. Neurol. 38, 589 (1995); P. K. Morrish, G. V. Sawle, D. J. Brooks, Brain 119, 585 (1996).
32. J. P. Seibyl et al, Ann. Neurol. 38, 589 (1995); P. K. Morrish, G. V. Sawle, D. J. Brooks, Brain 119, 585 (1996).
33. I. Shoulson and K. Kieburtz, in Neuroprotection: Fundamental and Clinical Aspects, P. R. Bär and M. F. Beal, Eds. (Dekker, New York, 1997), pp. 457-464.
34. S. W. Davies et al., Cell 90, 537 (1997); D. L. Price et al., NeuroScience News 1, 21 (1998); D. L. Price and S. S. Sisodia, Annu. Rev. Neurosci. 21, 479 (1998).
35. S. W. Davies et al., Cell 90, 537 (1997); D. L. Price et al., NeuroScience News 1, 21 (1998); D. L. Price and S. S. Sisodia, Annu. Rev. Neurosci. 21, 479 (1998).
36. S. W. Davies et al., Cell 90, 537 (1997); D. L. Price et al., NeuroScience News 1, 21 (1998); D. L. Price and S. S. Sisodia, Annu. Rev. Neurosci. 21, 479 (1998).
37. Reviewed in D. L. Price, S. S. Sisodia, D. R. Borchelt, Science 282, 1078 (1998).
38. J. M. Warrick et al., Cell 93, 939 (1998).
39. W. M. Pardridge, J. Cereb. Blood Flow Metab. 17, 713 (1997); R. Langer, Nature 392, 5 (1998).
40. W. M. Pardridge, J. Cereb. Blood Flow Metab. 17, 713 (1997); R. Langer, Nature 392, 5 (1998).
41. J. R. Sladek and I. Shoulson, Science 240, 1386 (1988).
42. Supported by grants from the Huntington's Disease Society of America (NY), the Hereditary Disease Foundation (CA), the National Parkinson Foundation (FL), the Parkinson's Disease Foundation (NY), and the Lucille P. Markey Charitable Trust. The thoughtful suggestions of K. Kieburtz, P. Leber, and D. Oakes are appreciated.